363 related articles for article (PubMed ID: 35533046)
1. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.
Menezes S; Okail MH; Jalil SMA; Kocher HM; Cameron AJM
J Pathol; 2022 Jul; 257(4):526-544. PubMed ID: 35533046
[TBL] [Abstract][Full Text] [Related]
2. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
3. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.
Neuzillet C; Nicolle R; Raffenne J; Tijeras-Raballand A; Brunel A; Astorgues-Xerri L; Vacher S; Arbateraz F; Fanjul M; Hilmi M; Samain R; Klein C; Perraud A; Rebours V; Mathonnet M; Bièche I; Kocher H; Cros J; Bousquet C
J Pathol; 2022 Dec; 258(4):408-425. PubMed ID: 36102377
[TBL] [Abstract][Full Text] [Related]
4. The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes.
Thorlacius-Ussing J; Jensen C; Nissen NI; Cox TR; Kalluri R; Karsdal M; Willumsen N
J Pathol; 2024 Jan; 262(1):22-36. PubMed ID: 37728068
[TBL] [Abstract][Full Text] [Related]
5. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.
Pereira BA; Vennin C; Papanicolaou M; Chambers CR; Herrmann D; Morton JP; Cox TR; Timpson P
Trends Cancer; 2019 Nov; 5(11):724-741. PubMed ID: 31735290
[TBL] [Abstract][Full Text] [Related]
6. Fibroblasts in pancreatic cancer: molecular and clinical perspectives.
Rebelo R; Xavier CPR; Giovannetti E; Vasconcelos MH
Trends Mol Med; 2023 Jun; 29(6):439-453. PubMed ID: 37100646
[TBL] [Abstract][Full Text] [Related]
7. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
8. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
Sperb N; Tsesmelis M; Wirth T
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.
Huang H; Brekken RA
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C233-C243. PubMed ID: 32432930
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting.
Vaish U; Jain T; Are AC; Dudeja V
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948209
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Zhang T; Ren Y; Yang P; Wang J; Zhou H
Cell Death Dis; 2022 Oct; 13(10):897. PubMed ID: 36284087
[TBL] [Abstract][Full Text] [Related]
14. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
[TBL] [Abstract][Full Text] [Related]
16. The role of stromal cancer-associated fibroblasts in pancreatic cancer.
von Ahrens D; Bhagat TD; Nagrath D; Maitra A; Verma A
J Hematol Oncol; 2017 Mar; 10(1):76. PubMed ID: 28351381
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
[TBL] [Abstract][Full Text] [Related]
19. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
20. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
